Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 690517 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Within Dose Groups) and Effect of Food on the Bioavailability of BI 690517 (Openlabel, Randomised, Two-way Cross-over)
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs BI 690517 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Nov 2017 Status changed from active, no longer recruiting to completed.
- 23 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 15 May 2017 Status changed from not yet recruiting to recruiting.